Showing results (171-180 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|December 3, 2014
Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestryAbenaa M Brewster, Mariana Chavez-MacGregor, Powel Brown
The Lancet. Oncology|December 4, 2014
Global burden of cancer attributable to high body-mass index in 2012: a population-based studyMelina Arnold, Nirmala Pandeya, Graham Byrnes, et al.
The Lancet. Oncology|November 6, 2015
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trialRolf A Stahel, Oliver Riesterer, Alexandros Xyrafas, et al.
The Lancet. Oncology|June 9, 2016
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trialJeffrey S Weber, Geoff Gibney, Ryan J Sullivan, et al.
The Lancet. Oncology|June 10, 2016
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialToni K Choueiri, Bernard Escudier, Thomas Powles, et al.
The Lancet. Oncology|May 27, 2019
Global childhood cancer survival estimates and priority-setting: a simulation-based analysisZachary J Ward, Jennifer M Yeh, Nickhill Bhakta, et al.
The Lancet. Oncology|May 3, 2019
Digital pathology and artificial intelligenceMuhammad Khalid Khan Niazi, Anil V Parwani, Metin N Gurcan
The Lancet. Oncology|May 13, 2019
Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trialSolveig Hofvind, Åsne S Holen, Hildegunn S Aase, et al.
The Lancet. Oncology|June 9, 2018
Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trialGunter von Minckwitz, Marco Colleoni, Hans-Christian Kolberg, et al.
The Lancet. Oncology|May 9, 2018
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trialSusanne Saussele, Johan Richter, Joelle Guilhot, et al.
Pageof 336